ProShare Advisors’s Sarepta Therapeutics SRPT Stock Holding History

ProShare Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-8,447	Closed	-$539K	–	2177
2025 Q1	$539K	Sell	8,447 -547	-6%	-$57.6K	﹤0.01%	1051
2024 Q4	$1.09M	Sell	8,994 -799	-8%	-$97.9K	﹤0.01%	874
2024 Q3	$1.22M	Sell	9,793 -493	-5%	-$68.2K	﹤0.01%	761
2024 Q2	$1.63M	Buy	10,286 +3,708	+56%	+$476K	﹤0.01%	691
2024 Q1	$852K	Buy	6,578 +601	+10%	+$73.6K	﹤0.01%	838
2023 Q4	$576K	Sell	5,977 -121	-2%	-$11.6K	﹤0.01%	963
2023 Q3	$739K	Buy	6,098 +71	+1%	+$8.03K	﹤0.01%	781
2023 Q2	$690K	Sell	6,027 -73	-1%	-$9.41K	﹤0.01%	817
2023 Q1	$841K	Sell	6,100 -2,491	-29%	-$323K	﹤0.01%	754
2022 Q4	$1.11M	Sell	8,591 -170	-2%	-$19.7K	﹤0.01%	719
2022 Q3	$968K	Buy	8,761 +512	+6%	+$51.6K	﹤0.01%	739
2022 Q2	$618K	Sell	8,249 -2,753	-25%	-$203K	﹤0.01%	876
2022 Q1	$859K	Sell	11,002 -3,448	-24%	-$264K	﹤0.01%	979
2021 Q4	$1.3M	Sell	14,450 -4,502	-24%	-$385K	﹤0.01%	905
2021 Q3	$1.75M	Buy	18,952 +1,734	+10%	+$134K	﹤0.01%	749
2021 Q2	$1.34M	Buy	17,218 +4,807	+39%	+$364K	﹤0.01%	878
2021 Q1	$925K	Sell	12,411 -1,189	-9%	-$110K	﹤0.01%	1039
2020 Q4	$2.32M	Sell	13,600 -409	-3%	-$60.6K	0.01%	596
2020 Q3	$1.97M	Buy	14,009 +352	+3%	+$53.5K	0.01%	574
2020 Q2	$2.19M	Buy	13,657 +2,099	+18%	+$286K	0.01%	544
2020 Q1	$1.13M	Sell	11,558 -6,254	-35%	-$715K	0.01%	576
2019 Q4	$2.3M	Sell	17,812 -3,973	-18%	-$401K	0.01%	588
2019 Q3	$1.64M	Sell	21,785 -1,569	-7%	-$185K	0.01%	631
2019 Q2	$3.55M	Sell	23,354 -3,529	-13%	-$429K	0.02%	475
2019 Q1	$3.2M	Buy	26,883 +1,033	+4%	+$133K	0.02%	499
2018 Q4	$2.82M	Sell	25,850 -3,451	-12%	-$432K	0.02%	501
2018 Q3	$4.73M	Buy	29,301 +1,763	+6%	+$241K	0.03%	431
2018 Q2	$3.64M	Sell	27,538 -10,158	-27%	-$958K	0.02%	505
2018 Q1	$2.79M	Sell	37,696 -6,198	-14%	-$413K	0.02%	551
2017 Q4	$2.44M	Buy	43,894 +3,592	+9%	+$190K	0.02%	564
2017 Q3	$1.83M	Buy	40,302 +7,503	+23%	+$300K	0.02%	579
2017 Q2	$1.11M	Sell	32,799 -2,227	-6%	-$72.5K	0.01%	707
2017 Q1	$1.04M	Sell	35,026 -9,093	-21%	-$281K	0.01%	736
2016 Q4	$1.21M	Buy	44,119 +9,080	+26%	+$365K	0.01%	695
2016 Q3	$2.15M	Sell	35,039 -4,257	-11%	-$129K	0.03%	466
2016 Q2	$749K	Buy	39,296 +10	+0%	+$185	0.01%	807
2016 Q1	$767K	Sell	39,286 -3,636	-8%	-$63.5K	0.01%	820
2015 Q4	$1.66M	Buy	42,922 +7,301	+20%	+$237K	0.02%	568
2015 Q3	$1.14M	Sell	35,621 -2,743	-7%	-$93.1K	0.02%	637
2015 Q2	$1.17M	Sell	38,364 -2,781	-7%	-$56.9K	0.02%	708
2015 Q1	$546K	Buy	41,145 +5,052	+14%	+$67.3K	0.01%	1133
2014 Q4	$522K	Sell	36,093 -1,152	-3%	-$19.5K	0.01%	1177
2014 Q3	$786K	Sell	37,245 -7,274	-16%	-$164K	0.01%	1162
2014 Q2	$1.33M	Sell	44,519 -22,315	-33%	-$705K	0.02%	1032
2014 Q1	$1.61M	Buy	66,834 +47,542	+246%	+$1.21M	0.02%	909
2013 Q4	$393K	Sell	19,292 -13,663	-41%	-$406K	0.01%	1101
2013 Q3	$1.56M	Buy	32,955 +26,874	+442%	+$1.04M	0.04%	549
2013 Q2	$231K	Buy	+6,081	New	+$217K	﹤0.01%	1921

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

ProShare Advisors's SRPT Position: Q2 2025 in Review

ProShare Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 8,447 shares — an estimated $539K sold.

ProShare Advisors first reported a position in SRPT in Q2 2013 and held it in 48 quarters. The position peaked at $4.73M in Q3 2018. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

ProShare Advisors reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
ProShare Advisors sold 8,447 Sarepta Therapeutics shares in Q2 2025, an estimated $539K.
ProShare Advisors first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 48 quarters.
ProShare Advisors's Sarepta Therapeutics position peaked at $4.73M in Q3 2018.
362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.